Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor

Kidney Int. 1999 Jan;55(1):271-7. doi: 10.1046/j.1523-1755.1999.00252.x.

Abstract

Background: Acute biliary obstruction is associated with the development of renal impairment and oxidative stress. The F2-isoprostanes, formed during oxidant injury, are renal vasoconstrictors acting via thromboxane (TX)-like receptors. We determined whether the formation of F2-isoprostanes is increased in experimental cholestasis and whether thiol containing antioxidants or ligands for the TXA2 receptor could improve renal function.

Methods: The effects on renal function of acute bile duct ligation (BDL) in the rat were studied for two days. The consequences of administration of N-acetylcysteine (NAC), alpha-lipoic acid (LA), the TX receptor antagonist (TXRA) BAYu3405, or placebo were then examined.

Results: BDL caused a reduction in creatinine clearance from 1.10 +/- 0.05 to 0.55 +/- 0.05 ml/min and sodium excretion from 52 +/- 3 to 17 +/- 3 micromol/hr. Urinary F2-isoprostanes increased from 14 +/- 2 to 197 +/- 22 pg/ml following BDL. Renal functional changes were ameliorated by NAC (creatinine clearance 0.73 +/- 0.05 ml/min), LA (0.64 +/- 0.03 ml/min), and a TXRA (0.90 +/- 0.15 ml/min); P < 0.05. Similarly, sodium excretion was increased from 17 +/- 3 micromol/hr (placebo) to 34 +/- 3 micromol/hr (NAC), 29 +/- 3 micromol/hr (LA), and 38 +/- 5 micromol/hr (TXRA); P < 0.005. Hepatic glutathione concentrations increased from 6.5 +/- 0.3 micromol/g (normal liver) to 8.8 +/- 0.5 micromol/g (NAC) and 7.7 +/- 0.3 micromol/g (LA), P < 0.01. However, only LA markedly inhibited F2-isoprostane formation (197 +/- 22 to 36 +/- 11 pg/ml creatinine clearance; P < 0.05). Urinary TXB2 excretion was elevated after BDL (2.2 +/- 0.5 to 111.1 +/- 20.3 pg/min) but was unaffected by NAC and LA.

Conclusion: NAC, LA, and TXRA can partially prevent renal dysfunction in experimental cholestasis. The effects of the antioxidants are independent of their ability to inhibit lipid peroxidation or TX synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / etiology*
  • Acute Kidney Injury / metabolism*
  • Animals
  • Antioxidants / pharmacology*
  • Carbazoles / pharmacology
  • Cholestasis / complications*
  • Cholestasis / drug therapy
  • Cholestasis / metabolism*
  • Dinoprost / urine
  • Glutathione / metabolism
  • Ligands
  • Lipid Peroxidation
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Thromboxane / antagonists & inhibitors
  • Receptors, Thromboxane / metabolism*
  • Sodium / urine
  • Sulfonamides / pharmacology
  • Thioctic Acid / pharmacology
  • Thromboxane B2 / urine

Substances

  • Antioxidants
  • Carbazoles
  • Ligands
  • Receptors, Thromboxane
  • Sulfonamides
  • Thromboxane B2
  • Thioctic Acid
  • Sodium
  • Dinoprost
  • Glutathione
  • ramatroban
  • Acetylcysteine